{Reference Type}: Journal Article
{Title}: Using Denosumab as a Nonsurgical Management of Aneurysmal Bone Cysts in the Pelvis.
{Author}: El Masry AM;Azmy SI;Mustafa MAR;Abuelhadid MA;
{Journal}: Clin Orthop Surg
{Volume}: 16
{Issue}: 1
{Year}: 2024 Feb
{Factor}: 2.503
{DOI}: 10.4055/cios22228
{Abstract}: <B>UNASSIGNED: </B>Aneurysmal bone cysts (ABCs) are infrequent, benign, and locally destructive lesions that most commonly occur during the first two decades of life. They usually affect the metaphysis of the long bones, but the pelvis is involved in 8%-12% of the cases. The management of pelvic ABCs is a challenging issue due to difficulties in choosing the appropriate approach, adjacent neurovascular bundles, the risk of intraoperative bleeding with difficulty achieving good hemostasis, and the risk of injury to the hip or sacroiliac joints. Limited data exist concerning the use of denosumab as a non-surgical treatment for pelvic ABCs. Our hypothesis was that denosumab might be an effective and safe solo treatment of cases with ABCs in the pelvis.<BR><B>UNASSIGNED: </B>We retrospectively assessed 20 patients with ABCs in the pelvis, who were treated by denosumab as a solo agent without surgery. Patients were assessed regarding disease control, the incidence of recurrence and non-oncological complications, and functional outcome.<BR><B>UNASSIGNED: </B>The mean follow-up period was 38.5 months. Disease control was achieved in 16 patients (80%), with no local recurrence. Tolerable drug-related complications occurred in 15% of cases. The mean Musculoskeletal Tumor Society score was 92.3%.<BR><B>UNASSIGNED: </B>Denosumab may provide a reliable option in the nonsurgical treatment of ABCs of pelvic origin with expected lower morbidity than the surgical solution and tolerable complications. Further studies on the safety profile and long-term effects of denosumab especially in skeletally immature patients are required.